SignalFDA/Bio

Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease

Positive Phase 3 data for dazodalibep in systemic Sjögren's disease drove Amgen up 7.9%.

What changed

Positive Phase 3 data for dazodalibep in systemic Sjögren's disease drove Amgen up 7.9%.

Why it matters

Positive Phase 3 data for dazodalibep in systemic Sjögren's disease drove Amgen up 7.9%. — impact context not separately stored; see What changed.

Sources